Instituto de Investigación Sanitaria Biobizkaia-ko ikertzaileekin lankidetzan egindako argitalpenak (30)

2023

  1. Endocannabinoid signaling in brain diseases: Emerging relevance of glial cells

    GLIA, Vol. 71, Núm. 1, pp. 103-126

  2. Hepatic levels of S-adenosylmethionine regulate the adaptive response to fasting

    Cell Metabolism, Vol. 35, Núm. 8, pp. 1373-1389.e8

  3. Spatial organization of neuron-astrocyte interactions in the somatosensory cortex

    Cerebral cortex (New York, N.Y. : 1991), Vol. 33, Núm. 8, pp. 4498-4511

  4. The endocannabinoid system and autoimmune demyelination: A focus on multiple sclerosis

    Neurobiology and Physiology of the Endocannabinoid System (Elsevier), pp. 229-240

  5. Therapeutic effect of α7 nicotinic receptor activation after ischemic stroke in rats

    Journal of Cerebral Blood Flow and Metabolism, Vol. 43, Núm. 8, pp. 1301-1316

2022

  1. Boosting Cholesterol Efflux from Foam Cells by Sequential Administration of rHDL to Deliver MicroRNA and to Remove Cholesterol in a Triple-Cell 2D Atherosclerosis Model

    Small, Vol. 18, Núm. 13

  2. Cannabinoid CB1 receptor expression in oligodendrocyte progenitors of the hippocampus revealed by the NG2-EYFP-knockin mouse

    Frontiers in Neuroanatomy, Vol. 16

  3. Cannabinoid CB1 receptor gene inactivation in oligodendrocyte precursors disrupts oligodendrogenesis and myelination in mice

    Cell Death and Disease, Vol. 13, Núm. 7

  4. Characterization of molecular biomarkers in cerebrospinal fluid and serum of E46K-SNCA mutation carriers

    Parkinsonism and Related Disorders, Vol. 96, pp. 29-35

  5. Genomic Multiple Sclerosis Risk Variants Modulate the Expression of the ANKRD55–IL6ST Gene Region in Immature Dendritic Cells

    Frontiers in Immunology, Vol. 12

  6. Identification of the genetic mechanism that associates L3MBTL3 to multiple sclerosis

    Human Molecular Genetics, Vol. 31, Núm. 13, pp. 2155-2163

  7. Pathophysiology of Atherosclerosis

    International Journal of Molecular Sciences, Vol. 23, Núm. 6

2021

  1. Astrocytic atrophy as a pathological feature of Parkinson’s disease with LRRK2 mutation

    npj Parkinson's Disease, Vol. 7, Núm. 1

  2. Fit-for-purpose based testing and validation of antibodies to amino- and carboxy-terminal domains of cannabinoid receptor 1

    Histochemistry and Cell Biology, Vol. 156, Núm. 5, pp. 479-502

  3. Novel transcript discovery expands the repertoire of pathologically-associated, long non-coding rnas in vascular smooth muscle cells

    International Journal of Molecular Sciences, Vol. 22, Núm. 3, pp. 1-16

  4. Δ9-Tetrahydrocannabinol promotes functional remyelination in the mouse brain

    British Journal of Pharmacology, Vol. 178, Núm. 20, pp. 4176-4192

  5. Δ9-Tetrahydrocannabinol promotes oligodendrocyte development and CNS myelination in vivo

    GLIA, Vol. 69, Núm. 3, pp. 532-545

2020

  1. A new risk variant for multiple sclerosis at 11q23.3 locus is associated with expansion of CXCR5+ circulating regulatory T cells

    Journal of Clinical Medicine, Vol. 9, Núm. 3

  2. An overground robotic gait training program for people with multiple sclerosis: A protocol for a randomized clinical trial

    Frontiers in Medicine, Vol. 7

  3. Birc6 is associated with vulnerability of carotid atherosclerotic plaque

    International Journal of Molecular Sciences, Vol. 21, Núm. 24, pp. 1-13